Suramin hexasodium salt
Cat. No. 1472
Chemical Name: 8,8'-[Carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt
Biological ActivityNon-selective P2 purinergic antagonist. Also blocks calmodulin binding to recognition sites and G protein coupling to G protein-coupled receptors. Increases open probability of ryanodine receptor (RyR) channels. Anticancer and antiviral agent.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Voogd et al (1993) Recent research on the biological activity of suramin. Pharmacol.Rev. 45 177. PMID: 8396782.
Beindl et al (1996) Inhibition of receptor/G protein coupling by suramin analogues. Mol.Pharmacol. 50 415. PMID: 8700151.
Charlton et al (1996) PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors. Br.J.Pharmacol. 118 704. PMID: 8762097.
Klinger et al (2001) Suramin and the suramin analogue NF307 discriminate among calmodulin-binding sites. Biochem.J. 355 827. PMID: 11311147.
Hill et al (2004) Functional regulation of the cardiac ryanodine receptor by suramin and calmodulin involves multiple binding sites. Mol.Pharmacol. 65 1258. PMID: 15102954.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Suramin hexasodium salt, supplier, Non-Selective, P2, antagonists, P2X, P2Y, Uncouples, G, proteins, from, receptors, heterotrimeric, purinoceptors
Find multiple products by catalog number
New Products in this Area
Potent P2X3 modulator
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.